Showing 2791-2800 of 4166 results for "".
- EyePoint Announces Positive 6-Month Results for the Phase 2 VERONA Clinical Trial of Duravyu for DMEhttps://modernod.com/news/eyepoint-announces-positive-6-month-results-for-the-phase-2-verona-clinical-trial-of-duravyu-for-dme/2482649/EyePoint Pharmaceuticals announced positive 6-month results for the ongoing phase 2 VERONA clinical trial evaluating Duravyu (vorolanib intravitreal insert) for diabetic macular edema (DME). Duravyu is an investigational sustained delivery therapy delivering vorolanib, a selective tyros
- 4DMT Announces Positive Interim Data from 4D-150 SPECTRA Clinical Trial in DMEhttps://modernod.com/news/4dmt-announces-positive-interim-data-from-4d-150-spectra-clinical-trial-in-dme/2482620/4D Molecular Therapeutics announced topline interim data from Part 1 of its SPECTRA clinical trial evaluating 4D-150 for the treatment of diabetic macular edema (DME). The company said it has achieved alignment with the FDA on the registrational pathway for 4D-150 in DME, advancing its
- AbbVie and Regenxbio Announce Updates on the ABBV-RGX-314 Clinical Program in DR and Wet AMDhttps://modernod.com/news/abbvie-and-regenxbio-announce-updates-on-the-abbv-rgx-314-clinical-program-in-dr-and-wet-amd/2482618/AbbVie and Regenxbio announced updates to the ABBV-RGX-314 gene therapy clinical program. Data from the ATMOSPHERE and ASCENT pivotal trials evaluating the safety and efficacy of the subretinal delivery of ABBV-RGX-314 in patients with wet AMD are expected in 2026. The co
- PulseSight Therapeutics Initiates Clinical Plan of PST-611 Transferrin Vectorized Therapy for Dry AMD/GAhttps://modernod.com/news/pulsesight-therapeutics-initiates-clinical-plan-of-pst-611-transferrin-vectorized-therapy-for-dry-amdga/2482615/PulseSight Therapeutics SAS announced it has submitted a clinical trial authorization (CTA) to Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM) for a phase 1 trial (PST-611-CT1) assessing the safety
- Ocugen Receives Health Canada Approval to Initiate Phase 3 Clinical Trial for Retinitis Pigmentosahttps://modernod.com/news/ocugen-receives-health-canada-approval-to-initiate-phase-3-clinical-trial-for-retinitis-pigmentosa/2482410/Ocugen announced that Health Canada has provided a “No Objection Letter” to initiate the phase 3 Limelight clinical trial for OCU400 in Canada. OCU400 is a modifier gene therapy product candidate designed for the treatment of retinitis pigmentosa (RP). "Expand
- Aldeyra Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalaphttps://modernod.com/news/aldeyra-therapeutics-achieves-primary-endpoint-in-phase-3-dry-eye-disease-clinical-trial-of-reproxalap/2482391/Aldeyra Therapeutics announced the primary endpoint has been achieved in its phase 3 trial of investigational reproxalap for dry eye disease. In the randomized, double-masked, vehicle-controlled dry eye chamber clinical trial, reproxalap 0.25% was statistic
- Aurion Biotech Completes Enrollment In Phase 1/2 Clinical Trial of Allogeneic Cell Therapy Candidatehttps://modernod.com/news/aurion-biotech-completes-enrollment-in-phase-12-clinical-trial-of-allogeneic-cell-therapy-candidate/2482306/Aurion Biotech announced that it has completed dosing of all subjects in its phase 1/2 clinical trial (CLARA) of AURN001, an allogeneic cell therapy for the treatment of corneal edema secondary to corneal endothelial dysfunction. “Aurion Biotech is delighted that both enrollm
- Dopavision Announces Topline Results in Clinical Trial of Targeted Photobiomodulation Approach for Progressive Myopiahttps://modernod.com/news/dopavision-announces-topline-results-in-clinical-trial-of-targeted-photobiomodulation-approach-for-progressive-myopia/2482295/Dopavision announced topline findings from its MyopiaX-1 proof-of-concept clinical trial (NCT04967287). MyopiaX delivers targeted photobiomodulation to the eye with the aim of managing the progression of myopia among children. The 6-month outcomes of the randomized, controlled tria
- Opthea Completes Enrollment in Pivotal Phase 3 Clinical Program with Sozinibercept in Wet AMDhttps://modernod.com/news/opthea-completes-enrollment-in-pivotal-phase-3-clinical-program-with-sozinibercept-in-wet-amd/2482294/Opthea announced that it has completed enrollment in both the COAST and ShORe trials constituting its pivotal phase 3 clinical program. This program is designed to assess the safety and superior efficacy of sozinibercept in combination with standard-of-care anti-VEGF-A therapies compared to
- Aurion Biotech Announces First Canadian Subject Dosed in Phase 1/2 Clinical Trialhttps://modernod.com/news/aurion-biotech-announces-first-canadian-subject-dosed-in-phase-1-2-clinical-trial/2482189/Aurion Biotech announced that it has dosed the first Canadian subject in its phase 1/2 clinical trial (ABA-1, CLARA) of AURN001, a cell therapy for the treatment of corneal edema secondary to corneal endothelial dysfunction. AURN001 is a combination cell therapy product (biologic/d